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38 Purpose. Cervical cancer is the most frequently diagnosed female cancer in The 
39 Gambia, representing approximately 30% of cases. In 2014, the quadrivalent human 
40 papilloma virus (HPV) vaccine was introduced, which offers protection against HPV 
41 genotypes 6, 11, 16 and 18.  To evaluate the potential effectiveness of this vaccine, 
42 genotype distribution and risk factor analysis were assessed. 
43 Methodology.  Endocervical samples (n=232) were collected from women aged 20-
44 49 years residing in urban Gambia. A questionnaire was administered to capture 
45 socio-demographic and cervical cancer risk factors. HPV detection and genotyping 
46 was performed by PCR amplification of the L1 major capsid gene and analysis of 
47 sequenced PCR products.
48 Results/ Key Findings. The prevalence of HPV was 12% (28/232) and the high risk 
49 (HR) genotype HPV 52 (5/28) was the most prevalent genotype. HR-HPV sequences 
50 had high identity (≥ 90 %) to isolates which originated from America, Europe and 
51 Asia but not from Africa. Half (14/28) of participants were co-infected with 
52 Ureaplasma urealyticum/parvum, which increases the risk of progression to cervical 
53 cancer. Female genital mutilation and the use of hormone contraception for >5 years 
54 were identified as potential risk factors for HPV infection. Ethnicity-associated 
55 differences were also noted; participants of the Fula ethnic group had a higher 
56 prevalence of HR-HPV infection (31.3%) compared to the Mandinka (18.8%) and 
57 Wollof (12.5%) groups.
58 Conclusion. These data may have a significant public health impact as the HPV 
59 quadrivalent vaccine may be of limited value if the circulating non-HPV 16/18 HR-













73 Human papilloma virus (HPV) infection is the most common sexually transmitted 
74 infection in reproductive aged females, and is associated with approximately 80% of 
75 cases of cervical cancer [1, 2]. More than 75% of sexually active females will be 
76 infected with the virus at some stage in their lives, which in some cases can regress 
77 without treatment [3, 4]. However, persistent infection with HPV high risk genotypes 
78 over a period of time can lead to cervical intraepithelial neoplasia (CIN), which can 
79 progress to cervical cancer [5, 6, 7].  Annually, more than 500,000 new cervical 
80 cancer cases and 250,000 deaths are reported, worldwide [8]. Although cervical 
81 cancer is a global health problem, more than 80% of these cases occur in Africa 
82 where regular cervical cancer screening programmes are not readily available. 
83 Cervical cancer survival rates are very low in developing countries due to either late 
84 presentation of cases or a lack of adequate treatment services [8, 9].
85 Approximately 100 HPV genotypes have been identified and 40 of these can infect 
86 the genital mucosal tract. According to the International Agency for Research on 
87 Cancer (IARC), twelve of these HPV mucosal types; HPV-16, 18, 31, 33, 35, 39, 45, 
88 51, 52, 56, 58 and 59 are termed high risk (HR–HPV) or oncogenic types [10]. HPV 
89 types 26, 53, 66, 67, 68, 70, 73 and 82 are classified as possible or probable high 
90 risk (pHR–HPV) [11]. Low risk (LR-HPV) types are associated mostly with 
91 condyloma acuminata, genital warts or other benign epithelial lesions. The most 
92 common LR-HPV genotypes are HPV-6 and HPV-11 [10, 12]. Although persistent 
93 infection with HR-HPV 16 and 18 are responsible for more than 70% of cervical 
94 cancer cases, other HR-HPV genotypes have been identified as causative agents for 
95 cervical cancer, and other genital and oropharyngeal cancers [12, 13]. While HPV 
96 infection is the major risk factor for the development of cervical cancer, several other 
97 co-factors are known to increase this risk [14]. These include having multiple sexual 
98 partners, the use of hormone contraceptives and smoking. Furthermore, co-infection 
99 with other sexually transmitted pathogens may enhance HPV persistence through 
100 immunosuppression and tissue damage, which can increase the risk of development 
101 of cervical neoplasia and cancer [15].
102 In an attempt to reduce the burden of HPV infection, three recombinant HPV 
103 prophylactic vaccines have been developed: a bivalent vaccine, manufactured by 
4104 GlaxoSmithKline that targets HR-HPV 16, 18,  a quadrivalent vaccine, marketed by 
105 Merck & Co, against HR-HPV 16, 18 and LR-HPV 6 and 11, and more recently 
106 Gardasil 9, from Merck & Co, has been licensed, which targets 7 HR-HPV genotypes 
107 16, 18, 31, 33, 45, 52, 58 and LR-HPV, 6 and 11.  
108 Although HPV infection is vaccine-preventable, widespread introduction of the 
109 vaccine in resource-limited countries is still in its infancy.  In the Gambia, cervical 
110 cancer is the most frequently diagnosed cancer, representing approximately 30% 
111 (161/545) of all diagnosed cases during the period 1998-2006 [16]. Furthermore, 
112 according to The Gambia Health Management Information System, 237 females 
113 were diagnosed with cervical cancer in 2016 and 96% of these cases were from the 
114 urban region of the country (Banjul, Kanifing Municipal Council (KMC) and West 
115 Coast Region (WCR)).
116 In 2014, The Gambia introduced the quadrivalent HPV vaccine in the WCR, targeting 
117 females from 9–13 years. However, the major circulating HR-HPV genotypes are 
118 currently unknown in this population; therefore there is a need to collect current data 
119 on HPV infection rates and circulating genotypes. The aim of the study was to 
120 evaluate the potential value of the quadrivalent vaccine in urban Gambia by 
121 investigating the major circulating HR-HPV genotypes in females residing in this 
122 area. In addition, the presence of known socio-demographic risk factors for HPV 
123 infection was also determined in this population as well as HPV co-infection with 
124 selected sexually-transmitted pathogens.
125 METHODS 
126 Study site and population 
127 This study focused on residents of Banjul, Kanifing Municipal Council and West 
128 Coast Region where the majority of cervical cancer cases are reported. Females, 
129 aged 20-49 years attending the Edward Francis Small Teaching Hospital (EFSTH) 
130 sexual health clinic, for primary health care were enrolled in this study. Informed 
131 consent (Figure S1) was obtained and a participant’s information sheet (Figure S2) 
132 was provided for those who agreed to participate.
133
5134 Socio-demographic and risk factors data collection
135 To determine the social and economic implications of HPV in urban Gambia, a 
136 questionnaire was administered to each participant to capture socio-demographic 
137 and potential risk factors associated with HPV infection (Figure S3).
138 Sample collection and routine microbiological investigations
139 Two hundred and thirty-five (235) females were recruited between August 2015 and 
140 February 2016. Two endocervical and two high vaginal swabs were collected from 
141 each participant, one endocervical and high vaginal swab from each patient was 
142 used for routine microbiological investigations and the remaining swabs for PCR 
143 amplification. Samples for PCR were placed immediately into specimen transport 
144 media (M4RT™, micro-test, Oxoid, Basingstoke, UK), and stored at -70oC until ready 
145 for use.
146 Routine microbiological detection of Streptococcus agalactiae, Candida albicans, 
147 Neisseria gonorrhoeae, bacterial vaginosis and Trichomonas vaginalis was 
148 performed in the Department of Medical Microbiology, EFSTH, using standard 
149 operating procedures. For the isolation of Streptococcus agalactiae, Neisseria 
150 gonorrhoeae and Candida albicans, high vaginal and endocervical swabs were 
151 cultured onto defibrinated sheep blood agar, chocolate agar and Sabouraud agar 
152 (Oxoid™, Basingstoke, UK). The blood and chocolate agar plates were incubated 
153 overnight at 37°C in an aerobic and a 6% carbon dioxide atmosphere, respectively. 
154 Sabouraud plates were incubated aerobically at 28°C for up to 48 hours to isolate 
155 Candida albicans or Candida species. Colonies of interest were subcultured and 
156 incubated overnight to generate pure colonies. These were selected for Gram 
157 staining and biochemical identification. Streptococcus agalactiae was identified using 
158 the Streptex™ rapid latex agglutination test (Thermo Fisher Scientific, 
159 Loughborough, UK), Neisseria gonorrhoeae was identified using the API NH test 
160 (Biomérieux, Basingstoke, UK) and Candida albicans was identified by a positive 
161 germ tube test. Trichomonas vaginalis was detected by vaginal wet mount 
162 microscopy for the detection of motile trichomonads. Bacterial vaginosis was 
163 diagnosed using Amsel’s clinical criteria, by the presence of any three of the 
164 following: 1) a homogeneous white vaginal discharge; 2) a vaginal pH of ≥ 4.6; 3) the 
165 release of a ‘fishy’ amine odour when 10% potassium hydroxide was added to a 
6166 vaginal fluid sample; 4) the presence of more than 20% clue cells as observed by 
167 microscopy [17].
168 DNA extraction
169 DNA was extracted from the clinical specimens using QIAamp DNA mini extraction 
170 kit (Qiagen, Crawley, UK) following the manufacturer’s instructions. To quality control 
171 the extraction process, sterile water was used as a negative control. A 5 µl volume of 
172 DNA was used in subsequent PCR reactions. Endocervical swabs were used for 
173 HPV PCR while both endocervical and high vaginal swabs were used for 
174 Ureaplasma parvum/urealyticum PCR.
175 Polymerase Chain Reaction  
176 All PCR amplifications were performed in a 25 µL volume containing 5 µM of each 
177 primer, 1x Taq PCR master mix containing 2.5 units of Taq DNA polymerase, 0.2 
178 mM deoxynucleotide trisphosphates, and 1.5mM MgCl2 (Qiagen, Crawley, UK) and 
179 5µl of DNA template. Amplified products were resolved by electrophoresis using 2% 
180 (w/v) agarose gels.
181 Histocompatibility Leucocyte Antigen PCR
182 To assess the quality of the DNA extracts from clinical specimens prior to HPV PCR 
183 testing, the presence (or absence) of human cellular DNA was determined using a 
184 PCR assay targeting the histocompatibility leucocyte antigen (HLA) gene. HLA-PCR 
185 was carried out using the forward primer 5’GTGGTGTAAACTTGTACCA-3’ and 
186 reverse primer 5’-GTAGCAGCGGTAGAGTT-3’, which amplified a 230 base-pair 
187 (bp) region. Thermal cycling was performed as described elsewhere [18]. A positive 
188 HLA-PCR test was determined by the observation of a visible PCR product of the 
189 expected size following gel electrophoresis and ethidium bromide staining. 
190 HPV Late gene L1 consensus PCR
191 HLA-PCR positive samples were subjected to PCR that amplifies a 450-bp region of 
192 the HPV late gene 1 (L1) using the PGMY09/11 consensus primers. The L1 
193 consensus PGMY09/11 primer pool consists of 5 upstream and 13 downstream 
194 oligonucleotides [18, 19]. A W.H.O. International standard HPV16 DNA positive 
195 control (NIBSC, Hertfordshire, UK), negative control (molecular grade water) and a 
7196 DNA extraction negative control were included in each PCR run. Thermal cycling 
197 was carried out as described elsewhere [18].
198 Ureaplasma parvum/urealyticum PCR
199 Conserved primers for two species of Ureaplasma (U. urealyticum and U. parvum) 
200 UU-1402 Forward 5’- TGCTGGTGGTACAGGTATGAA-3’and UU-1779 Reverse 5’-
201 GAGCATGTCCACCACCA -3’, were used, which target a 378 bp region of the 
202 urease gene [20]. Positive (Genekam Biotechnology, Duisburg, Germany), negative 
203 (molecular grade water) and DNA extraction negative controls were included in each 
204 PCR reaction. The thermal cycling consisted of an initial denaturation at 95oC for 3 
205 minutes, followed by 35 cycles of denaturation at 95oC for 30 seconds, annealing at 
206 58oC for 30 seconds, elongation at 72oC for 30 seconds and a final extension step at 
207 72oC for 5 minutes.
208 HPV genotyping by DNA sequencing
209 PCR amplicons were purified using a PCR purification kit (Sigma Aldrich, Haverhill, 
210 UK) and then sequenced using the Sanger chain termination method. Raw sequence 
211 data is provided in Table S1. An NCBI BLAST (http:// www.ncbi.nlm.nih.gov/BLAST/) 
212 search was performed for each sequenced product to allocate the HPV genotype 
213 [18].
214 Statistical analysis  
215 Data analysis on HPV prevalence and risk characteristics was carried out using Epi 
216 Info™ version 7 (CDC, Atlanta, USA). Descriptive statistics such as frequency 
217 distributions and percentages were used to describe HPV prevalence and other 
218 related characteristics of the study population. Bivariate and multivariate analyses 
219 were carried out on the strength of risk factors association with HPV infection using 
220 odds ratio (OR), adjusted odds ratio (AOR), confidence interval of 95% (CI) and a P 





226 Of the 235 participants recruited, 3 (1.3%) had samples where inadequate cellular 
227 DNA had been collected so were excluded from further analysis.
228 Socio-demographic and HPV risk characteristics of participants
229 A total of 232 females aged 20-49 years were included in the study with a mean age 
230 of 31.8 years (± 7.5 SD). Thirty percent of the participants were involved in petty 
231 trading as means of economic subsistence, whilst 26% of the participants identified 
232 as housewives. Eighty percent of participants were married and 48.3% of 
233 participants had at least 12 years of education. Three participants (1.3%) reported to 
234 be sexually inexperienced although they did not have an intact hymen and 6 (2.6%) 
235 participants reported to have their sexual debut at the age of <14 years as a result of 
236 early marriage. Sixty seven percent (67%) of participants had their sexual debut at 
237 the age of ≥18 years and approximately 40% reported of having ≥2 life time sexual 
238 partners. Sixty percent (60%) of participants reported their partners having other 
239 sexual partners and more than 80% reported never using a condom during sexual 
240 intercourse. Seventy eight percent (78%) reported using hormone contraceptives. 
241 Approximately 63% of participants underwent female genital mutilation (FGM). Table 
242 1 shows the socio-demographic and risk factor characteristics of participants, 
243 expressed in absolute values and percentages.
244 Multivariate analysis of HPV Risk Factors
245 Female genital mutilation (FGM), low annual income, fewer than 12 years of 
246 education and partners having other sexual partners were risk factors for HPV 
247 infection but not associated significantly with the infection (P>0.05). Hormone 
248 contraceptive use for >5 years was found to be a risk factor and was associated 
249 significantly with HPV infection (AOR 4.2, P=0.03) (Table 2). Participants who had 
250 their sexual debut at the age of ≥18 years were twice as likely to be infected with 
251 HPV (AOR 2.2, P=0.17). Being married was found to be a protective factor against 
252 HPV infection ; however, stratification analysis (not shown) indicated that married 
253 females who had sex in the preceding 12 months without using condoms were at 
254 increased risk of HPV infection (AOR 2.1, P>0.05). Table 2 shows the risk factor 
255 characteristics associated with HPV infection in this study.
9256 HPV Prevalence and genotype distribution
257 Of the 232 participants with adequate cellular DNA, HPV DNA was detected in 28. 
258 The overall HPV prevalence was found to be 12.1% with 9 different HR/ pHR and 7 
259 different LR genotypes identified. Twelve (42.9%) women were infected with a HR-
260 HPV genotype, 4 (15.4%) with pHR carcinogenic types and 12 (42.9%) with LR 
261 types. The most prevalent HR-HPV type detected was HPV 52 (17.9%), followed by 
262 HPV 51 and 58, each at 7.1% and the most prevalent pHR-HPV was HPV 66 (7.1%). 
263 HPV 61 was the most common LR-HPV genotype, accounting for 14.3% of all 
264 genotypes. 
265 HPV genotypes were allocated according to the IARC genotype classification using 
266 raw sequence data (Table S1) [10]. HPV genotypes with homology differences less 
267 than 2% to the closest known genotypes were identified as HPV variant types (99 -
268 100%) and those between 2% and 10% were identified as subtypes (90 - 98%). All 
269 HR/pHR-HPV genotypes identified in this study showed 98 -100 % identity to DNA 
270 sequences deposited in the GenBank database except one which was nominally 
271 allocated as a subtype of HPV genotype 35, although it showed only 82% identity to 
272 a known HPV 35 type (Table 3). The putative HPV 35 sequence was submitted to 
273 GenBank (accession number MH844101).  Furthermore, none of the HPV 
274 sequences identified were homologous to HPV sequences isolated in Africa.
275 HPV prevalence by age and ethnic group 
276 The HPV age-specific prevalence curve of participants showed a peak in the 21-25 
277 age group (32.1%), followed by a steady decline in the ages between 26 and 40 
278 years, and a sharp decline was seen in later years. However, HR-HPV prevalence 
279 was higher in the 26-30 age group (41.7%) and pHR-HPV types was higher in the 
280 21-25 age group (75%) (Table 4). HPV infection was not detected in the 20 year age 
281 group. Ethnicity-associated differences were also noted, HR/ pHR-HPV prevalence 
282 was higher in the Fulas (31.3%), followed by Mandinkas (18.8%) and a lower 
283 prevalence seen in the Wollofs (12.5%). However, LR-HPV genotypes were 
284 identified mostly in the Mandinka ethnic group, accounting for more than 40% of the 
285 LR types. The prevalence of both HR and LR-HPV genotypes was lower in the 
286 Wollofs compared to the other two major ethnic groups. The study also revealed a 
287 higher overall HPV prevalence in the Fula ethnic group (32.1%) and this group were 
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288 found to be more than twice at risk of HPV infection than the other two major ethnic 
289 groups (AOR 2.1, 95% CI 1.0, 4.9) (Table 2).
290 HPV and co-infection with other sexually-transmitted pathogens
291 Of the 28 females positive for HPV, 14 (50%) were co-infected with Ureaplasma 
292 parvum/urealyticum, 5 (18%) with Candida albicans, 3 (10.7%) with Streptococcus 
293 agalactiae, 1 (3.6%) with Trichomonas vaginalis and 4 (14.8%) were diagnosed with 
294 bacterial vaginosis. Of those positive for Ureaplasma parvum/urealyticum, 11 (79%) 
295 were infected in both the vagina and cervix, 2 (14%) in the cervix only and 1 (7%) in 
296 the vagina only. In addition, of the 14 HPV-positive females that were co-infected 
297 with Ureaplasma, 7 (50%) were additionally co-infected with either Candida albicans, 
298 Trichomonas vaginalis or were diagnosed with bacterial vaginosis.
299 DISCUSSION
300 The introduction of any HPV vaccine prevention strategy requires consideration of 
301 the major circulating HR-HPV genotypes in the population. HPV genotyping is very 
302 important in primary cervical cancer screening as persistent infections with HR 
303 genotypes can progress to cervical cancer, especially in females aged 30 years or 
304 older. The Gambia is a small country in West Africa with a population of less than 2 
305 million [21]. Females between the ages 15-65 years represent 52% of the population 
306 and most are at risk of being diagnosed with cervical cancer. The quadrivalent 
307 vaccine has been introduced in the urban region of the Gambia and this is the first 
308 report of HPV genotype distribution where most cervical cancer cases are reported. 
309 Overall HPV prevalence was found to be 12.1%, which is slightly lower than the 13% 
310 prevalence reported for rural Gambia, 18% in nearby Dakar, Senegal and 40.8% in 
311 Egypt [3, 22, 23]. Of the 28 HPV positive samples in this study, 12 (42.9%) were HR-
312 HPV genotypes and 4 (14.3%) were pHR-HPV genotypes. This is somewhat greater 
313 than the HR-HPV prevalence reported for Dakar, Senegal (17.4%) and for south-
314 western Nigeria (19.6%) [24, 25], where both studies targeted women from 18–80 
315 years old. The differences in prevalence seen in these studies could be attributed to 
316 the different age groups targeted or, perhaps more importantly could be due to 
317 variability of HPV genotypes in different geographical locations. The higher HR-HPV 
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318 prevalence seen in this study could also be reflecting selection bias, since cervical 
319 samples were collected from individuals who chose to attend a sexual health clinic.
320 HPV 52 was the most common high risk genotype identified, accounting for 31.3% of 
321 the total HR/ pHR-HPV genotypes and 17.9% of all genotypes. HPV 61 was the 
322 most frequent LR genotype identified with an overall prevalence of 14.3% and 
323 accounting for 33.3% of all LR-HPV.  In contrast to earlier work in rural Gambia, 
324 where HR-HPV 16 and LR-HPV 42 were the most common genotypes identified, this 
325 study showed that 89% of HPV genotypes identified do not match those included in 
326 the quadrivalent vaccine [22]. Similarly, work carried out in an urban region of 
327 Senegal, the only country to neighbour The Gambia also found that HPV 52 was the 
328 most common genotype [25]. The same observation was also seen in studies carried 
329 out in Kenya and Tanzania [2, 4, 26].This augments the findings of Bruni et al [1] that 
330 HPV 52 is a major genotype in Africa. 
331 HPV 16 and 18 are the predominant circulating genotypes found in Southern Africa, 
332 Europe and America. However, HPV 16 was found to be the fifth most common HR/ 
333 pHR genotype with a prevalence of 6.3%. HR-HPV 18 was detected in none of the 
334 samples. Although the burden of cervical cancer is higher in Africa compared to 
335 Europe and America, HPV 16 and 18 seems to lose its predominance as the major 
336 circulating genotype in some parts of Africa.  Studies in Africa have shown that other 
337 HR genotypes such as HPV 31, 35 and 58 are major circulating genotypes [27-30], 
338 indicating that the HPV bivalent and quadrivalent vaccine may not be as effective in 
339 Africa as previously thought [31-33]. Considering the high burden of cervical cancer 
340 cases and the lower prevalence of HPV 16 and 18 in Africa, it could be that other 
341 HR-HPV genotypes may be responsible for the high burden of the disease. In 
342 addition, a study in Asia found that HR-HPV 52 and 58 genotypes (3.8% and 5.6% 
343 respectively) were associated with a number of cases of invasive cervical cancer and 
344 high squamous intraepithelial lesions (HSIL) [34]. This finding further asserts the 
345 importance of determining the major circulating genotypes in a population before 
346 introduction of the HPV vaccine and is an important step in effective HPV infection 
347 prevention strategies.
348 It was shown here that 10.7% of participants were infected with HPV genotypes 
349 targeted by the quadrivalent vaccine and 35.7% were positive for HPV genotypes 
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350 included in the Gardasil 9 vaccine. This data may have important public health 
351 implications as the HPV quadrivalent vaccine may be of limited value for The 
352 Gambia if the circulating non-HPV 16, 18 HR-genotypes are responsible for cervical 
353 cytological abnormalities and progression to cervical cancer. 
354 DNA sequence analysis has shown that none of the HR/pHR-HPV genotypes 
355 detected were homologous to isolates from Africa found in the GenBank database, 
356 but rather isolates from America, Asia and Europe. This indicates that it is possible 
357 that these HR/pHR-HPV genotypes were imported into The Gambia (Table 3). This 
358 highlights a key difference with an earlier study in rural areas which found that many 
359 of the HR-HPV sequences were homologous to isolates from Africa [22]. 
360 Contributing factors may be linked to the fact that the urban area is a popular tourist 
361 destination therefore the lifestyle and sexual behaviour of the participants may be 
362 different. The isolate nominally allocated to HPV 35 may be a previously 
363 unrecognised type as the partial L1 gene sequence differed by more than 10% to the 
364 closest match, a HPV 35 genotype isolated in Ecuador (Table 3). Further work is 
365 required to determine this.
366 Infection with HPV is common in young females; however most of these infections 
367 are transient and regress within 12 months, with only a small percentage developing 
368 persistent infection [3, 35]. The high HPV prevalence peak seen in the 21-25 age 
369 group follows population norms of sexual initiation as 77.8% of the participants had 
370 their sexual debut at the age of ≥18 years. A sharp decline in prevalence was 
371 observed in those greater than 40 years old, which is consistent with viral transience. 
372 A similar finding was also observed in Abuja, Nigeria [27]. Studies carried out in 
373 Africa and Asia have reported a biphasic or a flat shaped HPV age-specific curve in 
374 older ages [23, 36]. However, 41.7% of the HR-HPV genotypes were found in the 
375 26-30 age group, which highlights the importance of early and regular HPV and 
376 cervical cancer screening. The study data also revealed that 93% of participants had 
377 never had cervical cancer screening (Table 1). This may be due to either lack of 
378 awareness about cervical cancer or accessibility to screening, or both. The Gambia 
379 Histopathology Laboratory is situated at EFSTH, Banjul and it is currently the only 
380 laboratory offering cytology in the country. In addition, there are no decentralised 
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381 national cervical cancer screening programmes therefore making access to 
382 screening a significant problem.
383 Whilst HPV infection plays a vital role in cervical cancer development, other socio 
384 and risk co-factors appear to contribute to the increased risk of disease progression. 
385 Bosch et al [37] have also showed that females who used hormone contraceptives 
386 for more than 5 years are at increased risk for developing cervical cancer and this 
387 work supports this assertion (Table 2). However, association studies on HPV positive 
388 females and long term use of hormone contraceptives have failed to reach 
389 consensus [38]. There is a potential association between HPV infection and 
390 prolonged use of hormone contraceptives in the development of cervical cancer, 
391 which needs addressing with a larger study population.
392 It was found that 98.9% of participants whose partners have other sexual partners 
393 are at increased risk of being infected with HPV (AOR 3.5; P=0.30) but not 
394 associated significantly with HPV infection (Table 2). Married participants who had 
395 sexual intercourse in the last 12 months without using condoms were found to be 
396 twice at risk of acquiring HPV infection when compared with unmarried participants 
397 (AOR 2.1, P>0.05). This interaction may be linked to polygamy, which is a common 
398 practice in The Gambia and Africa and has implications of increased frequency of 
399 sexual activity with more than one partner.  In The Gambia, 39% of females live in a 
400 polygamous union with one or more co–wife [39], which increases the risk of 
401 acquiring and transmitting HPV. Furthermore, 91.7% (22/24) of participants who 
402 were HPV-infected reported not using a condom during sexual intercourse in the 
403 preceding 12 months. The majority (80.6%) of the respondents were married and are 
404 less likely to report using condom during sexual intercourse than unmarried women. 
405 Another contributing factor could also be poor negotiating power with their partners 
406 on condom use during sexual intercourse, especially those in polygamous 
407 relationship. However, using condoms in the preceding 12 months was found to be a 
408 protective factor against HPV infection (AOR 0.7, 95% CI 0.2-35).
409 As also reported by Wall et al [22], this study found that HPV infection was higher in 
410 the Fula ethnic group and this group were significantly more susceptible to HPV 
411 infection (AOR 2.1; P=0.15) (Table 2). Similarly, Sighoko et al [16] also noted an 
412 ethnicity variation in their study on cervical cancer in The Gambia. They found the 
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413 Fula ethnic group were more at risk of being diagnosed with cervical cancer 
414 compared to the other ethnic groups. The differences seen in the prevalence of HPV 
415 infection in the different ethnic groups may be linked to possible genetic factors as 
416 previously reported [16, 22, 40], or FGM being a predisposing factor. FGM is a 
417 common cultural practice amongst certain ethnic groups of The Gambia and more 
418 than 50% of females have undergone FGM before the age of 5 years. However, 75% 
419 of females aged 15-49 years had undergone FGM in the Gambia with slightly higher 
420 burden of 79% seen in the rural area compare to 72% in the urban area [39]. Data 
421 on FGM showed that all the Fula (9/9) females who were infected with HPV 
422 underwent FGM. In The Gambia, Wollof females are least likely to have had FGM 
423 and were found to be at reduced risk for HPV infection (AOR 0.5; P=0.35). In 
424 contrast to male circumcision, which is thought to be a protective factor against HPV 
425 infection in males and their female partners [41, 42], this study showed that 
426 participants that have undergone FGM were twice likely to be at risk of being 
427 diagnosed of HPV infection (AOR 2.1; P=0.12), however FGM was not found to be 
428 associated significantly with HPV infection. Similarly, studies of Senegalese and 
429 Malian females also found FGM to be a risk factor for HPV infection [43, 44]. FGM is 
430 practised in many African countries especially in north-eastern Africa where HPV 
431 and cervical cancer burdens are high. The association between FGM and HPV 
432 infection could be a result of genital tissue damage leading to chronic inflammation 
433 making these females more susceptible to infection. Furthermore, since most 
434 females with FGM are susceptible to recurrent genital infections, this can result in an 
435 impaired immune response and therefore can lead to an inability to clear HPV 
436 infection.
437 It was shown that 50% of participants infected with HPV were co-infected with 
438 Ureaplasma parvum/urealyticum. Others have also found a high prevalence of 
439 Ureaplasma in females with high grade squamous intraepithelial lesions (HSIL) 
440 compared to those with normal cytology [45, 46]. Although Ureaplasma 
441 parvum/urealyticum infections are known to be sexually-transmitted, they are often 
442 not diagnosed and treated. These microorganisms can cause chronic pelvic 
443 inflammatory disease and infertility if left untreated. In addition, Ureaplasma can 
444 damage the vaginal epithelium and causes cervical mucus degradation thus 
445 potentially facilitating HPV progression to cervical cancer [47]. This work adds to the 
15
446 body of evidence that Ureaplasma infection is an important co-factor in HPV infection 
447 and highlights the importance of testing for Ureaplasma parvum/urealyticum and 
448 providing appropriate treatment to HPV-infected females, especially those with 
449 abnormal cytological results.
450 In conclusion, there is an apparent difference between the major, circulating HR-
451 HPV genotypes in urban and rural areas of The Gambia; however, both studies 
452 underscore the need for a multivalent vaccine that targets all major HR-HPV 
453 genotypes in the general population. Although, the quadrivalent vaccine has been 
454 piloted in The Gambia, this study raises important public health issues with HPV 
455 vaccination programmes in developing countries. The introduction of accessible HPV 
456 DNA testing and cytology screening would be beneficial to Gambian women in 
457 cervical cancer prevention. In this work, participants were not screened for cervical 
458 cancer and future studies to investigate HPV genotype distribution from cervical 
459 cancer specimens would be necessary for enhanced cervical cancer intervention 
460 strategies in The Gambia. 
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Table 1. Univariate analysis of socio-demographic and risk factors of study participants (n= 
232)
Characteristics Number Percentage (%)
Residence
Banjul 104       44.8
KMC /WCR 128       55.2
Age group (years)
20     7        3.0
21-25   53      22.8
26-30   57      24.6
31 -35   46      19.8
36-40   33      14.2
>40   36      15.5
Ethnic group
Mandinka   57     24.6
Fula   49     21.1
Wollof   42     18.1
Jola   20       8.6
Serere   30     12.9
Others   34     14.7
Education level
None   37     16.0
Primary   38     16.4
Secondary   99     42.7
College   13       5.6
Quaranic studies   45     19.4
Occupation
House wife   61     26.3
Petty trading   71     30.6
Business   37     16.0
Civil servant   24     10.3
Others   39     16.8
Annual Income
<D75,000 (USD 1,563) 180     77.6
>D75,000 (USD 1,563)   52     22.4
Marital status
Married 187     80.6
Single   45     19.4
Age of sexual debut*
<18 years   75     32.8
≥18 years 154     67.2
Life time sexual partner(s)*
1 138     60.5
≥2   91     39.7
Partner(s) have other sex partners**
Yes   84     60.8
No   52      37.7
Don't know     2        1.4
Condom use (last 12 months)
Yes    22      10.4
No  189      89.6
23
FGM
Yes 145     62.5
No   87     37.5
Past screening for cervical cancer
Yes   14       6.1
No 218     93.7
Family member diagnosed with cervical cancer
Yes     5       2.2
No 227     97.8
Hormone contraceptive use
Yes 181     78.0
Never   50     21.6
Yes, but stopped     1       0.4
645 *3 Participants reported never having a sexual relationship
646 **Only participants that reported having 1 lifetime sexual partner were asked this 
647 question













Table 2. Risk factor characteristics associated with HPV infection
Characteristics         HPV DNA results
ǂ Adjusted OR (95% 
CI)         P-value
Age group
<21 0 7                                                                                                                                                                     
21-25 9 44             1.5 (0.6, 3.6)              0.52
26-30 7 50          
31-35 5 41               
36-40 5 28               
>41 2 34              
Ethnic Group#
Fula 9 40            2.1 (1.0, 4.9)               0.15
Mandinka 8 49            1.2 (0.4, 2.7)               0.94
Wollof 3 39            0.5 (0.1, 1.7)               0.35
Age of sexual debut
≥18 years 23 131            2.2 (0.8, 6.2)               0.17
<18 years 5 70
Marital status
Married 23 164           0.9 (0.3, 2.5)               0.91
Single 5 40
FGM
Yes 21 124           2.1 (0.9, 5.7)               0.12
No 7 80
Education
<12 years 11 109           2.0 (0.9, 4.5)               0.16
≥ 12years 17 95
Lifetime sexual partner(s)
≥2 14 77           1.8 (0.8, 4.1)              0.23
  1 14 124
Partner(s) have other sex 
partners
Yes 13 99           3.5 (0.4, 28)              0.30*
No 1 27
Hormone contraceptive use




(USD1563) 20 160          1.7 (0.5, 5.5)              0.51
>D75,000 
(USD1563) 8 44
Condom use in last 12 months
Yes 2 20           0.7 (0.2, 3.3)             0.95*
No 23 166
660    # Major ethnic group, *Fisher’s exact test used due to sample size 
              Positive (28)       Negative 
(204)     
(27)
25
661 ǂ Mantel Haenszel odds ratio- adjusted for age
662  Table 3 Comparison of HR/pHR HPV DNA sequences from this study with isolates 
663 deposited in the GenBank database









16 KY549284 C484604r11164343NP Netherlands 98
35 KU050113 ECU-08 Ecuador 82
51 KF707619 R60 Switzerland 98
KJ676061 R72 Switzerland 99
52 KF707618 CRO 1F6 Croatia 99
EU077215 23 Canada 100
EU077215 23 Canada 100
EU077215 23 Canada 100
KY077858 KOR_M10-    4515 South Korea 99
53 KU951263 CN10 China 99
56 KU298919 110A.56 Brazil 99
58 HM63967 ww100HK_973 Hong Kong 99
HQ537776 Rw644 New York,   
USA
99
66 KU298927 83A.66 Brazil 98
KU298928 118A.66 Brazil 98




666 Table 4.   HPV genotype distribution amongst the different age groups
667
668 Age group (years)
21-25 26 -30 31 - 35 36 - 40 41 - 49
              6   51   16      6    42 
35   52   51   52    54 
52   52   58   61 
HPV genotype 53*   52   61   61
54   58   62   83
56   61
66*   66
73* 
89 
669 Genotypes: Bold; high risk HPV, *; probable high risk HPV and non-bold; low risk HPV.  None of the 











680   Figure S1. Participant consent form used in this study
681
682 PARTICIPANT CONSENT FORM
683
684 Project Title: Human Papilloma Virus co-infection with Sexually Transmitted Pathogens 
685 amongst women of reproductive age in urban Gambia
686 Statement by subject
687  I have read the written information OR
688  I have had the information explained to me by study personnel in a language that I 
689 understand* 
690 and I
691 confirm that my choice to participate is entirely voluntarily,
692 confirm that I have had the opportunity to ask questions about this study and I am satisfied 
693 with the answers and explanations that have been provided,
694 understand that I grant access to identifiable data about me to authorised persons described 
695 in the information sheet,
696 am aware that part of my sample will be taken abroad for further analysis
697 agreed for my sample to be stored for future research
698 have received time to consider to take part in this study,
699 agree to take part in this study. 
700
701 Participant Details




706 Contact number…………………                          ----------------------- - - - - - - - - - - - - - - -
707                                                                           Signature/Thumbprint of volunteer:  







715 * Only required if the participant is unable to read or write
716
717 This form has been read by / I have read the above to 
718   _ _ _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ _ _ _ _ _  (Write name of volunteer)
28
719 in a language that she understands. I believe that she has understood what I explained and that 
720 she has freely agreed to take part in the study.
721 Signature of field worker: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
722 Name of field worker: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
723 Date: |___|___| / |___|___| / |___|___|___|___|
724
725 Contact for further information 
726 If you have any problem or query about any aspect of the study at any time, please 
727 do not hesitate to contact the researcher or the Hospital Public Relation Officer 
728 (PRO) on the contacts given below: 
729
730 EFSTH PRO                                   Momodou Lamin Jammeh
731                                                         Email: jammehdux@gmail.com
732                                                         Tel:  9900598, 7934110











741 Figure S2. Participation Information sheet used in this study.
742
743 PARTICIPANT INFORMATION SHEET
744
29
745 Project Title: Human Papilloma Virus co-infection with Sexually Transmitted 
746 Infection Pathogens amongst women of reproductive age in urban Gambia
747 You are kindly invited to take part in a research project, designed by Haddy Bah 
748 Camara of Edward Francis Small Teaching Hospital (EFSTH), Banjul, The Gambia in 
749 collaboration with the University of Westminster (UoW), London, UK. Mrs. Haddy Bah 
750 Camara and the study team will provide you with all the information concerning the 
751 project and your participation. Do not hesitate to contact the study team if there is 
752 anything you do not understand. You can confirm your participation by signing or 
753 thumb-printing the consent form below.
754
755 What is the purpose of the study?
756
757 The purpose of this study is to determine whether women infected with sexually 
758 transmitted bacteria will also be infected with Human Papilloma Virus, which can 
759 cause cervical cancer. The study involves collaboration with Edward Francis Small 
760 Teaching Hospital, Gambia and University of Westminster, UK
761 The results from the study will help in making health policies on HPV and STI 
762 management in Gambia; provide education to the community and serve as foundation 
763 for future researches on HPV in Gambia. 
764
765 What will you be asked to do?
766
767 Participation in this study is voluntary. Swab or blood specimens will be collected from 
768 you as part of your routine clinic appointment. A sterile cotton swab will be introduced 
769 into your cervix (womb) to collect the sample or a sterile syringe and needle will be 
770 introduced into your vein to collect a venous blood sample (where applicable). This 
771 will be done by an experienced staff of the clinic in the safest way possible. You have 
772 every right to withdraw from the exercise if you are uncomfortable or unwell. 
773
774 Risks and Discomfort
775 It is very unlikely that there will be any side effects for taking part in the study.  You 
776 may experience slight discomfort when swab / blood sample are being taken. However 
777 this will be done in the safest way possible.
778
779
780 Why have I been ask to participate?
30
781 You have been asked to participate because of your present condition and history of 
782 infection /Non existing infection (Family Planning client)
783
784 Do I have to take part?
785 Participation is voluntary. However, if you decide to take part, a copy of this information 
786 sheet will be given to you to keep. You are free to withdraw at any time without giving 
787 reasons and can request the removal of your sample from the study. Moreover your 
788 decision to withdraw will not affect the health care you receive.
789
790 What do I have to do?
791 In order to be recruited for the study, you are kindly requested to answer some few 
792 questions below. You can then confirm your participation by signing/ thumb printing 
793 the consent form below.
794
795 Confidentiality
796 This is a student research project which may be published.  In the course of the project 
797 and in the event of subsequent publication, your participation and any other personal 
798 details will be kept highly confidential.  Your sample will be given a specific research 
799 number and anonymized.  Access to identifiable data will be held in Gambia only by 
800 your respective health provider, who has access to your information. Dr Patrick 
801 Kimmitt, Dr Edward Wright and Haddy Bah Camara will only handle anonymized 
802 samples with no bearing to your identity.
803
804
805 Expenses and Payments
806 Participation is entirely voluntary and as such there will be no payment for your 






































844 Please allow me 15 minutes of your time to answer the following questions. Your genuine 
845 answers will help the health care provider to make corrective decisions in providing quality 
846 health care. Your answers will be kept confidential and known only to the care provider. Your 
847 identity will not be distributed, published or sold.
848
849
850 1.  Health facility 
851
852 Name……….    Type…………
853
854 2   Participant Identifier number …………
855
856





861 5. What is the purpose of your visit today? 
862
863 __ Family Planning visit (go to Question. 7)    
864
865 __ STI   visit, (go to Question. 6) 
866
867 __ HIV management visit (go to Question. 7)    
868
869 6.  . Do you have any of the following symptoms today? (Tick)
870
871 __Vaginal itching\ discharge with fishy or strong odour 
872 __Pain or burning when urinating  
873 __bleeding between periods 
874 __Pain during sex     
875 __Sores, skin rashes with rough red or reddish brown spots on hands or feet 
876 __Genital warts 
877 __ Lower abdominal pain 
878 __Others (specify) ……………
879 • If YES to any of the questions, find out how long she has/had the symptoms------
880
881
882 SECTION B: Socio economic background
883
884 7. What is your ethnicity? (Tick)
885
886    __ Wollof
887
888    __ Mandika
889
890    __ Jola
891
892    __ Serere
893
894    __ Sarahule
895
896    __ Fula
897
898    __ Others (Specify)
899
900 8. What is the highest level of education you have completed? (Tick)
901
902      __ None
903
904      __ Primary level
905
906      __ Secondary level
33
907
908      __ College
909
910      __ University
911
912      __ Quaranic studies
913
914 9. What is your current occupation? (Tick)
915
916       __ Student
917
918      __ Petty trader
919
920      __ Business woman
921
922     __ Civil servant
923
924    __ House wife
925
926    __ Farmer
927
928    __ Others (specify)
929
930 10. How many people are currently living in your household, including yourself? ___
931
932 a. Of these people, how many are children ≤18 years old? ___
933
934
935 11. Which of these categories best describes your total combined family income for your 
936 household for the past 12 months? (Tick)
937
938 __ <D10, 000 
939
940 __ D 10,000 - 35,000
941
942 __ D35, 000 - 50,000 
943
944 __ D51, 000 – 65,000 
945 __ D66, 000 – 75,000
946 __ D 76,000 – 85,000
947 __ D85, 000 - 100,000 
948 __ > D100, 000 
949 __ Don’t Know / Not sure 
950
951 12. Have you ever smoked cigarettes? (Tick)
952
953 __ Yes (How many a day?) Specify_
954 __ No
955 __ Quit 
34




960 __ Don’t Know
961 __Not sure
962




967 __ Don’t Know
968
969 15. This visit, swab samples will be collected from you by a health care provided, but would 
970 you have preferred to collect the samples yourself? 
971
972 __ Yes.(if yes, why?)
973          -  Embarrassment
974           - Others ………… (Specify)




979 SECTION C: Reproductive and Hormonal factors
980
981 B. Menstrual periods
982 16. At what age did your menstrual periods begin? (Tick)
983 __ 10 years
984 __ 11 years
985 __ 12 years
986 __ 13 years
987 __ 14 years
988 __ 15 years
989 __ 16 years
990 __ 17 years or older
991
992 17. Have you had a menstrual period within the last 12 months? (Tick)
993 __ Yes, I still have a menstrual cycle (go to question18)
994 __ Yes, but my menstrual cycle stopped within the last year 
35
995 __ No, my menstrual cycle stopped more than one year ago
996 __ Don’t know
997
998 18. When was your last menstrual period? 
999 |___||___| / |___||___||___||___| OR |___||___|
1000 Month YEAR AGE
1001 __ Don’t know 
1002
1003 19. Which of these best describes why your menstrual cycle stopped? (Tick)
1004 __ Breastfeeding
1005 __ Birth control or medications
1006 __ Natural menopause
1007 __ Surgery to remove the uterus or ovaries
1008 __ Other (specify) ________________________
1009 __ Don’t know
1010
1011 Pregnancy
1012 20. Have you ever been pregnant? (Tick)
1013 __ No (go to question 24)
1014 __ Yes
1015 __ Don’t know (go to question 24)
1016
1017 21. How old were you when you first became pregnant? (Tick)
1018 __ Less than 15 years
1019 __ 15-19 years
1020 __ 20-24 years
1021 __ 25-29 years
1022 __ 30-34 years
1023 __ 35-39 years
1024 __ 40-44 years
1025 __ 45 years or older
1026 __ Don’t know 
1027
1028 22. How many times have you been pregnant? Please include stillbirths, miscarriages, 










1038 SECTION D. Contraceptive use
1039 23. Did you ever take birth control pills for birth control or to regulate menstrual periods? 
1040 (Tick)
1041 __ No, never (go to question 28)
1042 __ Yes
1043 __ Yes, but stopped taking them now (go to question 25 & 26)
1044
1045 24. How old were you when you first started taking birth control pills? (Tick)
1046 __ less than 15 years
1047 _ 15-19 years
1048 __ 20-29 years
1049 __ 30-39 years
1050 __ 40-49 years
1051
1052 25. How old were you when you last took birth control pills? (Tick)
1053 __ Still taking birth control pills
1054 __ Less than 15 years
1055 __ 15-19 years
1056 __ 20-29 years
1057 __ 30-39 years
1058 __ 40-49 years
1059 __ 50 years or older
1060
1061 26. How many total years of birth control pills have you used? (Tick)
1062 __ less than 5 years
1063 __ 5-9 years
1064 __ 10-14 years
1065 __ 15-19 years
1066 __ 20-24 years
37
1067 __ 25-29 years
1068 __ 30-34 years
1069 __ 35 years or more
1070 *Could repeat 14-17 for injectable contraceptive or shot, contraceptive hormonal patch, 





1076 SECTION E. WOMAN’S SEXUAL HISTORY
1077
1078 The next questions are about your sexual history.  I realize this is a personal subject, but it is 
1079 very important to the study. Please take the time to recall the information as accurately as 
1080 possible.  I want to remind you that this is a private interview and that the information you 
1081 give me will not be linked to your name. 
1082
1083 27. Are you married? (Tick)
1084
1085  __ Married*, (Is this your first married)? 
1086
1087        __ Yes (go to question 28)
1088





1094 __Widow    
1095




1100 __ Don’t Know
1101




1106 __NEVER HAD INTERCOURSE
1107















1122 IF NUMBER OF MEN = 1 …………………………..CONTINUE
1123 IF NUMBER OF MEN = GREATER THAN 1 ...........Q.34
1124 IF DON’T KNOW ......................................................Q.35
1125
1126
1127 31. Did your partner have any other sexual partners besides yourself, either before he met 




1132 __ Don’t Know
1133
1134 32. Besides yourself, how many sexual partners would you say he had? 
1135
1136          |__|__| 
1137
1138 NUMBER OF PARTNERS
1139
1140 __ Don’t Know
1141
1142 33. Would you say it was . . .  (READ)
1143
1144 __ 2 or 3,
1145
1146 __Between 4 and 6, 
1147
1148 __Between 7 and 10
1149
1150 __ More than 10
1151
1152  __ DON'T KNOW
1153
1154 34. Within the last year, have you had sexual intercourse?
1155
1156 __ Yes (go to 34b)
1157                34b. Does your partner (s) use condoms during sexual intercourse?
1158                      ---Yes




1162 35. During the last year, what is the total number of men with whom you have had sexual 
1163 intercourse?
1164
1165 |__|__| (go to question 38)
1166









1176 __ between 3 and 5
1177 __ >5
1178
1179 37. Within the last year, were any of these partners new partners, that is, partners with 




1184 38. With how many new partners did you have sexual intercourse in the last year?
1185
1186           |__|__| 
1187
1188 NUMBER OF NEW PARTNERS
1189
1190 __ DON'T KNOW 
1191
1192 39.  Would you say it was……… (READ)
1193
1194   __ 1
1195   __ 2
1196   __ between 3 and 5
1197   __ >5
1198
1199





1205 Table S1. Raw sequence data of high and low risk HPV genotypes identified by DNA sequencing 
1206 and nucleotide BLAST search (L1 gene, 450bp)
40
1207
1208 HR- High risk genotype; pHR – Presumptive high risk genotype; LR- Low risk genotype
1209
1210
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